A Clinical Trial Comparing BiVap (Richard Wolf®) Saline Vaporization of
The Prostate vs. TwisterTM Diode Laser System in The Treatment of Benign
Prostatic Obstruction Between Prostate Volume 90 to 150 ml.
Introduction:To evaluate the efficacy, safety and postoperative outcomes
of the BiVap saline vaporization and Twister™ Diode Laser systems with
benign prostatic obstruction (BPO) in prostate volüm between 90-150 ml.
Methods:In total, we included 131 patients treated with BiVap system
(n=68) and Twister system (n=63). Postoperative complications including
urinary tract infection, transient hematuria, severe dysuria and fever
>38° C, urinary incontinence and urethral stricture were
also noted. All patients were evaluated at the postoperative 1st, 3rd,
6th and 12th month and preoperative and postoperative values of IPSS
score, QoL score, total PSA, IIEF 15, PVR, Qmax and Qave were compared.
Statistical analyses were performed with SPSS version 18. A
P-value<0.05 was considered significant. Results:Preoperative
demographic characteristics were similar in the 2 groups. There was
observed significant improvement for IPSS, Qmax, Qave, PVR, and QoL
score by the postoperative first month compared to the preoperative
values in both groups. Maximum improvement in the IPSS, Qmax, Qave, QoL
score and PVR were achieved at postoperative 6, 3, 12, 3 and 12th months
respectively in group 1. In group 2 maximum improvement in the IPSS,
Qmax, Qave, QoL score and PVR were achieved at postoperative 6, 3, 6, 6
and 12th months, respectively. There was no significant difference
between the two groups in terms of IPSS, Qmax, Qave, QoL score, PSA,
PVR, IIEF-EF and IIEF-OS during the 1 year follow-up period
postoperatively. Conclusions:BiVap and Twister systems are safe,
effective, and useful technique, which can be used in the surgical
treatment of BPO between 90-150ml.